TY - JOUR T1 - 3-hour genome sequencing and targeted analysis to rapidly assess genetic risk JF - medRxiv DO - 10.1101/2022.09.09.22279746 SP - 2022.09.09.22279746 AU - Miranda Galey AU - Paxton Reed AU - Tara Wenger AU - Erika Beckman AU - Irene J. Chang AU - Cate R. Paschal AU - Jillian G. Buchan AU - Christina M. Lockwood AU - Mihai Puia-Dumitrescu AU - Daniel R. Garalde AU - Joseph Guillory AU - Androo J. Markham AU - Andrew B. Stergachis AU - Michael J. Bamshad AU - Evan E. Eichler AU - Danny E. Miller Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/09/13/2022.09.09.22279746.abstract N2 - Rapid genetic testing in the critical care setting enables targeted evaluations, directs therapies, and helps families and care providers make informed decisions about goals of care. We tested whether we could perform ultra-rapid assessment of genetic risk for a Mendelian condition, based on information from an affected sibling, in a newborn via whole-genome sequencing using the Oxford Nanopore platform. By optimization of the DNA extraction and library preparation steps paired with targeted analysis, we were able to demonstrate within three hours of birth that the newborn was neither affected nor a carrier for variants underlying acrodermatitis enteropathica. This proof-of-concept experiment demonstrates how prior knowledge of familial variants can be used to rapidly evaluate an individual at-risk for a genetic disease.Competing Interest StatementJG, AJM, and DRG are employees of Oxford Nanopore Technologies (ONT). DEM has received travel support from ONT to speak on their behalf. DEM and EEE are engaged in a research agreement with ONT. EEE is a scientific advisory board (SAB) member of Variant Bio, Inc. DEM holds stock options in MyOme.Funding StatementThis work was supported, in part, by a trainee grant to DEM from the Brotman Baty Institute for Precision medicine, and a US National Institute of Mental Health (NIMH) grant R01MH101221 to EEE. EEE is an investigator of the Howard Hughes Medical Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of the University of Washington gave ethical approval for this work. The legal representatives of both individuals described in this report consented to having the results of this research work published.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData that support the findings of this study are available upon request from the corresponding author. Additional clinical information about the individuals described here are available upon request from the corresponding author. ER -